ReviewEuropean journal of medical research2015
A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation.
Review in European journal of medical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Differential gene expression in nasal airway epithelium from overweight or obese youth with asthma.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2022Pooled it
- Psoriatic arthritis subtypes are phenocopied in humanized mice.JCI insight · 2024Article
- Interleukin-32 positive immune and resident cells in kidney samples from lupus patients: a pilot study.Frontiers in immunology · 2024Article
- Interleukin-32 as a biomarker in rheumatic diseases: A narrative review.Frontiers in immunology · 2023Review
- Natural killer cells in sepsis: Friends or foes?Frontiers in immunology · 2023Review
- Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy.Cancer cell · 2022Article
- Circulating IL-32 and IL-33 levels in patients with asthma and COPD: a retrospective cross-sectional study.Journal of thoracic disease · 2022Article
- Platelet-Released Growth Factors Influence Wound Healing-Associated Genes in Human Keratinocytes and Ex Vivo Skin Explants.International journal of molecular sciences · 2022Article
- Effects of IL-32 polymorphisms and IL-32 levels on the susceptibility and severity of coronary artery disease.Journal of clinical laboratory analysis · 2022Article
- Cascade of immune mechanism and consequences of inflammatory disorders.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2021Review
- Gene coexpression networks reveal novel molecular endotypes in alpha-1 antitrypsin deficiency.Thorax · 2021Article
- Inhibition of IL-32 Expression Ameliorates Cerebral Ischemia-Reperfusion Injury via the NOD/MAPK/NF-κB Signaling Pathway.Journal of molecular neuroscience : MN · 2020Article
- Interleukin 32 expression in human melanoma.Journal of translational medicine · 2019Article
- Role of IL-32 Gamma on Bone Metabolism in Autoimmune Arthritis.Immune network · 2018Review
- Diverse Expression of IL-32 in Diffuse and Intestinal Types of Gastric Cancer.Gastroenterology research and practice · 2018Article
- Role of TGF-β in anti-rhinovirus immune responses in asthmatic patients.The Journal of allergy and clinical immunology · 2017Article
- Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets.BMC rheumatology · 2017Review
- IL-32θ: a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity.American journal of translational research · 2017Review
- IL-32: A Novel Pluripotent Inflammatory Interleukin, towards Gastric Inflammation, Gastric Cancer, and Chronic Rhino Sinusitis.Mediators of inflammation · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokines have always been of great interest due to their vast potential and participation in the progression and pathogenesis of various ailments. Interleukin-32 (IL-32) is a recently identified cytokine, whose gene is located on human chromosome 16 p13.3, with eight exons and six splice variants (IL-32α to IL-32ζ). IL-32α, the most abundant form, is secreted by different types of cells including T cells, natural killer (NK) cells, monocytes, endothelial cells and epithelial cells. It acts as a preferential mediator and effector of abnormal immune responses to multiple inflammatory and auto immune diseases including rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), etc. It was found to stimulate the induction of various chemokines, pro-inflammatory cytokines including IL-1β, IL-6, IL-8, TNF-α and macrophage inflammatory protein-2 (MIP-2). Hence, IL-32 mediates the crucial interplay among immune system and body cells during pathogenesis of various insults. The aim of the present effort is to summarize the role, mechanism of pathogenesis and potential therapeutic applications of IL-32 in different systemic infections and diseased conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.